drugset

drugset / Trial / NCT00645892

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645892 ↗

Phase 2 Completed 32 enrolled Abbott

RandomizedParallel-groupDouble-blindTreatment

Summary

Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Timeline

Start: 2003-11
Primary completion: 2004-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Adalimumab	Monoclonal antibody	40 mg	—

Indications